ReviewBiomedicines2024
Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in asthmatic children: a systematic review with meta-analysis.European journal of pediatrics · 2026Pooled it
- Shared Mechanistic Pathways in Bullous Pemphigoid, Chronic Spontaneous Urticaria, Prurigo Nodularis, and Chronic Prurigo of Unknown Origin: Implications for Targeted Therapies.American journal of clinical dermatology · 2026Review
- Article
- IL-5Rα-Mediated Signaling in Eosinophils May Contribute to the Epithelial-Mesenchymal Transition in Eosinophilic Chronic Rhinosinusitis With Nasal Polyps.Journal of rhinology : official journal of the Korean Rhinologic Society · 2026Article
- Anti-Inflammatory Interleukins in the Pathogenesis of Atherosclerosis.International journal of molecular sciences · 2026Review
- The Role of and Therapeutic Strategies for Eosinophils in Atopic Dermatitis.Biomedicines · 2026Review
- Preliminary Effects of Benralizumab in an AML Cell Model with Promyelocytic Features Expressing IL-5R: An Exploratory Proof-of-Concept Study.Biomedicines · 2026Article
- Evaluation of Attachment Styles in Patients with Chronic Pruritus.Journal of clinical medicine · 2026Article
- Eosinophils in lung cancer: from inflammatory cytokines to immunotherapeutic biomarkers.Frontiers in immunology · 2026Review
- Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Frontiers in immunology · 2026Review
- Traditional Chinese medicine-related interventions for allergic conjunctivitis and vernal keratoconjunctivitis: clinical evidence, mechanistic hypotheses, and ocular surface safety considerations.Frontiers in medicine · 2026Review
- The Expanding Role of ILC2s in Allergic Airways Disease.Allergy · 2026Review
- Adjuvant-Free Murine Models of Allergic Sensitization to the Major Soybean Allergen Gly m 4.International journal of molecular sciences · 2025Article
- Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management.Journal of proteome research · 2025Review
- Advancements in Biologic Therapies for Pediatric Asthma: Emerging Therapies and Future Directions.Cureus · 2025Review
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.Biomolecules · 2025Review
- A multidimensional analysis of prognostic factors in atopic dermatitis.Frontiers in medicine · 2025Review
- IL-5, IL-31 and systemic immune-inflammation index as biomarkers predicting severity and progression in bullous pemphigoid.Frontiers in medicine · 2025Article
- Efficacy Analysis of a 12-Cytokine Panel for the Diagnosis of Kawasaki Disease and Prediction of Intravenous Immunoglobulin Resistance.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-5 functions as a B-cell differentiation factor, but more importantly, in the context of this review, it plays a variety of roles in eosinophil biology, including eosinophil differentiation and maturation in the bone marrow, and facilitates eosinophil migration to tissue sites, usually in the context of an allergic reaction. Given the availability of selective anti-IL-5 drugs such as mepolizumab and reslizumab, as well as the IL-5 receptor antagonist benralizumab, it is worth investigating whether they could be used in some cases of allergic disease. Asthma has a well-documented involvement of IL-5 in its pathophysiology and has clear benefits in the case of anti-IL-5 therapy; therefore, current knowledge is presented to provide a reference point for the study of less-described diseases such as atopic dermatitis, chronic rhinosinusitis, chronic spontaneous urticaria, and its association with both IL-5 and anti-IL-5 treatment options. We then review the current literature on these diseases, explain where appropriate potential reasons why anti-IL-5 treatments are ineffective, and then point out possible future directions for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.